Sol-Gel Technologies announced positive topline results from two pivotal phase 3 clinical trials for Twyneo (microencapsulated benzoyl peroxide, 3% and microencapsulated tretinoin, 0.1%) for the treatment of acne vulgaris.
The FDA has approved Arazlo (tazarotene; Ortho Dermatologics) Lotion 0.045% for the treatment of acne vulgaris in patients aged 9 years and older.
LEO Pharma announced positive topline results from three pivotal phase 3 studies of tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis.
The FDA has granted Fast Track designation to lebrikizumab for the treatment of moderate-to-severe atopic dermatitis.
Nemolizumab is a first-in-class humanized monoclonal antibody that blocks the signaling of IL-31 by targeting IL-31 receptor alpha.
Minocycline foam 4% (Amzeeq; Foamix) appears to be safe and effective for moderate-to- severe acne, according to findings from a long-term, open-label safety study.
The FDA has issued a report assembled by the inter-agency Drug Shortages Task Force to determine the root causes of drug shortages, and to offer recommendations based on the insights from stakeholders in the private and public sectors to help prevent future drug shortages.
Results found that 82% of patients in the combined group achieved PASI 90 and IGA 0/1 at week 204.
Bimekizumab met both co-primary end points as well as key secondary end points demonstrating superior to ustekinumab and placebo at Week 16.
The URGENT/11 vulnerabilities exist in a third-party software, called IPnet.
